Privo Technologies, Inc. Awarded $2.5M from National Cancer Institute for its Intraoperative Treatment of Solid Tumors

Peabody, MA — Privo Technologies, Inc. (“Privo”, “the Company”), a clinical stage biopharmaceutical company focused on optimizing state-of-the-art oncology treatments announced today that it has received $2.5M grant as part of National Cancer Institute’s Notice of Special Interest announcement. The award...

BIO International Convention 2021

Privo Technologies, Inc.  attends the BIO International Convention online from June 14-18, 2021. Despite the conference being held online this year due to COVID-19, Bio International 2021 was informative and enjoyable. The company connected with potential investors and industry partners in discussing...

Contact Us
close slider

Contact Us